Brianjh wrote a post · Aug 9 00:11

Eli Lilly Q2 FY24

Mounjaro, Zepbound, and Verzenio drive growth.

• Revenue +36% Y/Y to $11.3B ($1.3B beat).
• EPS $3.92 ($1.16 beat).

FY24 guidance (high end):
• Revenue +$3.0B to $46.6B.
• EPS +$0.29 to $14.00.

Credit image to: App Economy Insights

$Eli Lilly and Co (LLY.US)$ $Vanguard S&P 500 ETF (VOO.US)$ $SPDR S&P 500 ETF (SPY.US)$ $iShares Core S&P 500 ETF (IVV.US)$ $Invesco QQQ Trust (QQQ.US)$ $Invesco NASDAQ 100 ETF (QQQM.US)$

Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more

Translate

Report

154K Views

Comment

Brianjh

Moo Contributor

Posting Weekly content- Currently a part-time finance student Swing Trades + Long-term investing

2243Followers

35Following

5299Visitors